Purchase this article with an account.
Thomas Papathomas, Myrto Tsagkataki, Indu Kumar, Ahmed Kamal; Safety and efficacy of Dexamethasone Intravitreal Implant in Macular Edema due to Retinal Vein Occlusions - 1 year follow-up. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3840.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Dexamethasone Intravitreal Implant 0.7 mg (Ozurdex®) has been recently approved by NICE in UK for the treatment of Macular Edema (ME) secondary to venous occlusions. We present our series of patients treated with Ozurdex® implant for ME secondary to retinal vein occlusions at a tertiary referral centre. Our purpose is to evaluate the outcomes, efficacy and safety of Intravitreal Ozurdex® Implant.
Retrospective study of 90 eyes with ME due to retinal vein occlusion. Two thirds had branch retinal vein occlusion (BRVO), one third had central retinal vein occlusion (CRVO). All patients received the Ozurdex® implant. Best Corrected Visual Acuity (BCVA) using Logmar charts and Central Foveal Thickness (CFT) with OCT were evaluated at baseline, at 2 weeks and thereafter every 2 months following the procedure. Maximum follow-up time is 14 months. Any per-operative and post-operative complications were recorded.
At 2 weeks follow-up mean BCVA in BRVO improved from 0.52 to 0.47 and in CRVO from 0.90 to 0.66. Mean CFT improved from 424.7µ to 301.7µ in BRVO and from 585.2µ to 420.7µ in CRVO. No per-operative complications were noted. Fourteen patients had increased intraocular pressure responsive to topical antiglaucoma therapy. One patient required antiglaucoma surgery to control intraocular pressure. No Retinal complications were recorded. Majority of patients (62%) required retreatment at 18 weeks.
Dexamethasone Intravitreal Implant is an effective and safe option to maintain visual and anatomical success in retinal vein occlusions. The average effective time of the implant is 18 weeks.
This PDF is available to Subscribers Only